ERBB2 and breast carcinoma: The hormone receptor positive(HR+)/human epithelial growth factor receptor 2 positive(HER2+), triple-negative and HR-/HER2+ subtypes are more prevalent among the younger breast cancer patients, who are also more likely to present with more advanced stages of the disease (III/IV) compared to older women (3).